Dissociation, defined plainly
Dissociation is one of those clinical words that does heavy lifting in a wide variety of contexts. In psychiatry, it can mean a trauma-driven sense of detachment that protects a person from overwhelming experience. In ketamine medicine, it means something different: a temporary, drug-induced shift in how the brain integrates sensation, body awareness, and the sense of self. Same word, different mechanism, different clinical meaning.
If you have heard descriptions like “floating,” “watching myself from the outside,” or “the room felt far away,” that is the experiential signature most patients use to describe ketamine dissociation. The body feels lighter. Time stretches and compresses. Thoughts arrive in unusual sequences. Emotions can be noticed without being grabbed by them. None of this is hallucination in the psychotic sense; insight is preserved, and patients understand that the experience is being produced by the medication.
Ketamine is FDA-approved as an anesthetic; its use for depression, anxiety, PTSD, and chronic pain is off-label. The dissociative state is a known feature of subanesthetic ketamine, not a side effect to be eliminated. Whether it is necessary for therapeutic benefit is a separate question we will come back to.
How it is measured: the CADSS scale
Researchers do not assess dissociation by asking patients to describe their experience in free language. They use a structured tool called the Clinician-Administered Dissociative States Scale, or CADSS. The scale was developed and validated by Bremner and colleagues in a 1998 paper published in the Journal of Traumatic Stress. It captures present-state dissociative symptoms across three domains: depersonalization (feeling detached from the self), derealization (feeling detached from surroundings), and amnesia. CADSS is now the standard instrument in nearly every modern ketamine clinical trial.
What the scale gives clinicians is a number. That number lets researchers compare experiences across patients and across studies in a way that pure description cannot. It also lets us see the dose-response relationship clearly: as ketamine plasma levels rise, CADSS scores rise, and as ketamine clears the body, scores fall. The pattern is reliable enough that CADSS scores are sometimes used to confirm that a study dose actually produced the expected pharmacological effect.
CADSS is not a measure of severity in the danger sense. A higher score does not mean something has gone wrong. It means the medication is doing what it does at that dose for that person on that day.
What ketamine dissociation actually feels like
Krystal and colleagues anchored the modern understanding of ketamine’s subjective effects in a landmark 1994 paper published in Archives of General Psychiatry. In healthy volunteers, subanesthetic ketamine produced dose-dependent perceptual changes, mild thought disorganization, and feelings of unreality. The experience was time-limited and resolved as the drug cleared. Decades of subsequent work have refined these observations but have not overturned the basic finding.
Patients in our clinic describe the experience in remarkably consistent ways. The body feels weightless or pleasantly heavy. Visual experiences may shift, particularly with eyes closed. A sense of spaciousness opens in the mind, and worries that felt urgent before the infusion can feel distant or oddly small. Some patients report a quality of insight: stuck thought patterns become visible from a different angle. Others simply rest in a calm, dreamlike state without any verbal narrative attached.
Importantly, patients almost always remain oriented enough to communicate. If you need anything during the session, you can ask. The state is internally rich but not paralyzing. Our walkthrough of a first infusion describes the practical arc in more detail, from the room setup through the come-down period.
How it differs from anxiety or trauma dissociation
This is where patients are most often confused, and the confusion matters. Pathological dissociation, the kind associated with PTSD, complex trauma, dissociative identity disorder, and severe anxiety, is a defensive response. The nervous system, faced with experience it cannot integrate, partitions awareness to protect the person. It tends to feel cold, flat, frightening, and out of the person’s control. Patients describe losing time, feeling unreal in a distressing way, or watching their own life as if behind glass.
Ketamine-induced dissociation is mechanistically different. It is produced by NMDA-receptor antagonism, which temporarily quiets a specific glutamatergic circuit and, with it, the brain’s ordinary process of integrating signals into a unified sense of self and surroundings. The state usually feels neutral or pleasant, comes on gradually with the infusion, peaks predictably, and resolves as the drug clears. It is also occurring inside a clinical context the patient has consented to, in a room they trust, with a clinician present.
The distinction is not just academic. Patients with significant trauma histories sometimes worry that ketamine will trigger the kind of dissociation they associate with their worst episodes. In practice, most patients report that the two experiences feel different from the first session, and many find ketamine sessions calming rather than triggering. That said, this is a real conversation to have with your clinician before scheduling. We review trauma history during the consultation and adjust dose, environment, and pre-medications to suit the person in front of us.
Is dissociation required for ketamine to work?
This is one of the most studied open questions in the field, and the honest answer is that the evidence is mixed.
Luckenbaugh and colleagues, in a 2014 paper in the Journal of Affective Disorders, analyzed dissociation and antidepressant response across 108 patients with treatment-resistant depression. They found that higher CADSS scores during the infusion correlated with greater antidepressant response at 24 hours and at one week. The correlation was statistically significant, but it was not strong enough to predict outcome at the individual level, and the authors were careful not to overclaim. Subsequent studies have produced a mix of replications and non-replications.
What this body of evidence supports is that dissociation may be a marker of central NMDA engagement, and that engagement is part of what produces antidepressant effects. What it does not support is the idea that you must dissociate strongly, or that more is automatically better. Some patients respond well with modest dissociation. Some patients dissociate vividly and respond modestly. The relationship is real but loose.
Practically, this means we do not aim for a target CADSS score. We aim for a session that feels therapeutic and well tolerated, at a dose appropriate to the patient and the indication. The broader research on how ketamine reshapes neural circuits suggests that the antidepressant signal is built over the hours and days following the infusion, not solely in the dissociative window itself.
What clinicians watch for during the infusion
Ketamine’s safety profile at subanesthetic doses is well established, but it is still a potent medication, and competent monitoring is part of why it works as a clinical treatment rather than a recreational one. Our overview of ketamine safety covers the broader picture; here is what specifically applies during the dissociative window.
At Music City Ketamine, Marla Peterson, CRNA, oversees every infusion. Continuous pulse oximetry, automated blood pressure cycling, and heart-rate tracking run throughout the session. Ketamine modestly raises blood pressure and heart rate in most patients; this is expected, dose-dependent, and rarely clinically significant, but it is monitored attentively and addressed if a parameter drifts outside the planned range. CRNA-led, anesthesia-level monitoring is part of why this medication can be administered safely outside of a hospital.
Beyond vital signs, the clinician is watching for subjective comfort. If the dissociation is more intense than the patient prefers, infusion rate can be slowed or paused, and pre-medications such as low-dose benzodiazepines or anti-nausea medications can be adjusted in subsequent sessions. The room is quiet, the lighting is low, and the patient has access to support if they need it. The intent is a session that feels safe enough that the dissociative state can do its work without the patient bracing against it.
After the session: returning to baseline
The dissociative state resolves predictably. Most patients are back to a clear baseline within 30 to 60 minutes of the infusion ending. By the time they leave the clinic, they are conversational, oriented, and steady on their feet, though still mildly altered enough that we require a driver. By the next morning, the residual physical effects have faded, and what remains is whatever therapeutic shift the session set in motion.
Memory of the session is usually intact in broad strokes. Patients tend to recall themes, images, emotional tones, and the general arc of the experience the way a vivid dream is recalled the morning after. Specific moment-to-moment details may be blurred. This is normal and not a sign that anything went wrong. Some patients find journaling within an hour of the session helpful for capturing impressions before they fade.
What we encourage patients to track over the days that follow is mood, sleep, irritability, intrusive thoughts, and pain levels, depending on the indication. The therapeutic signal often unfolds gradually rather than arriving as a single moment of relief. Sessions are typically $475 each, and the protocol is built across multiple sessions because the cumulative pattern, not the individual session, is where the durable benefit sits.
Honest expectations matter. Ketamine does not work for everyone. Dissociation, while typically well tolerated, is not enjoyable for every patient, and not every patient responds robustly to the medication. If a session feels off, we adjust. If the protocol does not produce benefit after an adequate trial, we say so. The goal is not to push patients through a fixed treatment plan; it is to find out, as efficiently as possible, whether ketamine is the right tool for the situation in front of us.